Mirion Technologies (MIR)
Supplies radiation measurement and safety systems for nuclear operations, cancer care, laboratories, and defense.
Something off on this page? Send us feedback.
Sells radiation detection, monitoring, analysis, and safety systems through Nuclear & Safety and Medical. Revenue comes from instruments, software, services, and recurring calibration or replacement work spanning nuclear-plant lifecycles, laboratory and defense applications, radiation-therapy quality assurance, nuclear medicine, and worker dosimetry.
Supplies radiation detection, measurement, and monitoring products, software, and services through Nuclear & Safety and Medical. Nuclear & Safety covers reactor instrumentation across construction, operation, maintenance, and decommissioning, plus laboratory analysis, defense detection, regulatory compliance, and engineered components. Medical provides radiation-therapy quality assurance, nuclear-medicine products, and occupational dosimetry.
Serves utilities, reactor developers, hospitals, cancer centers, laboratories, governments, and militaries across North America, Europe, and Asia. Long-lived installed equipment creates replacement, calibration, upgrade, and service work; Certrec and Paragon extend the nuclear portfolio into licensing and obsolescence management.
Competes on reliability, technical qualification, and support in markets governed by strict specifications. Nuclear demand follows plant construction, operating-life extensions, maintenance, and decommissioning; medical demand depends on provider budgets, reimbursement, and evolving safety standards.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 3, 2026 | Jefferies | Initiate | Rating: —Target: — | Target: $20 |
| Aug 10, 2026 | Morgan Stanley | Target | Target: $25 | Target: $23 |
| Jul 30, 2026 | Northland Securities | Target | Target: $29 | Target: $24 |
| Jul 29, 2026 | Goldman Sachs | Reiterate | Rating: —Target: $25 | Target: $23 |
| Jul 13, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $27 | Target: $25 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $425.3M · Total debt $1.23B · Total assets $3.52B · Shareholders' equity $1.83B
- Revenue
- $266.8M
- Operating income
- $17.9M
- Net income
- $7.7M
No dividends on record.
| Institutions | 106.18% | 264.44M shares | |
|---|---|---|---|
| 375 holders · as of Jun 30, 2026 | |||
| Insiders | 0.08% | 203.6K shares | |
| 3 holders · as of May 7, 2026 | |||
| Adds to | 106.26% | ||
249.04M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 106.26%; nothing is left for Other.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 15.36% | 38.26M A | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 7.30% | 18.18M A | as of Jun 30, 2026 |
T. Rowe Price Investment Management, Inc.Institution | 5.74% | 14.29M A | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.26% | 10.61M A | as of Jun 30, 2026 |
Goldman Sachs Group IncInstitution | 4.18% | 10.41M A | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 2, 2026 | Brian Schopfer | officer: Chief Financial Officer | +20,000 | $15.60 |
| May 7, 2026 | Christopher A. Moore | officer: Chief Accounting Officer (PAO) | −8,400 | $19.64 |
| Dec 10, 2025 | Lawrence D. Kingsley | director | −350,000 | $24.73 |
| Nov 21, 2025 | Lawrence D. Kingsley | director | −300,000 | $23.83 |
| Nov 10, 2025 | Emmanuelle Lee | officer: Chief Legal Officer | −12,500 | $27.41 |
- Thermo Fisher Scientific
Broadest direct overlap in radiation detection and dosimetry
- Fortive
Direct dosimetry and safety-monitoring peer through Landauer
- AMETEK
ORTEC overlaps in nuclear detectors and spectroscopy systems
- Teledyne Technologies
FLIR overlaps in radiological search and CBRN defense sensing
- Curtiss-Wright
Nuclear plant safety systems overlap after Ultra Energy deal
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Mirion Technologies | $16.38 | +1.05% | $3.94B | 173.2 | 27.8 | 3.8 | +19.7% |
| Thermo Fisher Scientific | $658.93 | +0.03% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Fortive | $55.75 | +1.21% | $16.64B | 32.4 | 17.9 | 3.9 | −27.8% |
| AMETEK | $245.59 | +1.81% | $55.29B | 35.3 | 28.1 | 7.0 | +15.0% |
| Teledyne Technologies | $611.93 | +0.47% | $28.23B | 29.4 | 24.0 | 4.4 | +9.8% |
| Curtiss-Wright | $555.17 | −2.26% | $20.98B | 39.1 | 34.6 | 5.7 | +5.4% |
| Median | 35.3 | 25.1 | 5.3 | +9.8% |